-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immune checkpoint inhibitors (ICI) have become key treatments for many cancers, including clear cell renal cell carcinoma (ccRCC)
.
However, only some patients can benefit, and it is difficult to identify responders from non-responders
Only some patients can benefit, and it is difficult to identify responders from non-responders.
Currently, Immune Checkpoint Inhibitors (ICI) have become a key drug for the treatment of clear cell renal cell carcinoma (ccRCC), but their efficacy is limited and responders cannot be identified
.
Recently, researchers from Japan published an article in the journal Eur Urol.
They used RNA sequencing data from 311 patients to investigate the significance of PARP1 in ccRCC.
These patients have participated in a prospective clinical trial of PD-1 blockade..
These patients participated in the prospective clinical trial of PD-1 blockade .
The significance of PARP1 in ccRCC was investigated.
These patients all participated in the prospective clinical trial of PD-1 blockade.
The results of the study found that among patients treated with nivolumab (n=181), the overall survival rate (OS) of the lower PARP1 expression group was significantly higher than that of the higher PARP1 group (p=0.
006), and the PARP1 status was significantly related to OS (risk Ratio [HR] 1.
7; p=0.
007)
.
In contrast, for patients treated with everolimus (n=130), PARP1 status had no significant effect on progression-free survival (PFS; p=0.
In addition, in patients with PBRM1 mutant ccRCC treated with nivolumab, PARP1 status was significantly correlated with PFS (HR 2.
6; p=0.
007) and OS (HR 3.
5; p=0.
016)
.
Progression-free survival and overall survival of patients with advanced clear cell renal cell carcinoma treated with Nivolumab
Progression-free survival and overall survival of patients with advanced clear cell renal cell carcinoma treated with NivolumabIn summary, PARP1 can be used as a biomarker to predict the response of PBRM1 mutant ccRCC patients to ICI treatment
.
In addition, immune checkpoint inhibitors (ICI) are key drugs for the treatment of many cancers
PARP1 can be used as a biomarker to predict the response of PBRM1 mutant ccRCC patients to ICI treatment PARP1 can be used as a biomarker to predict the response of PBRM1 mutant ccRCC patients to ICI treatment
Original source:
Original source:Masayuki Hagiwara, Atsushi Fushimi, Kazuhiro Matsumoto et al.
Leave a message here